Döbling Private Hospital
Myeloma treatment cost in Austria typically includes essential diagnostics like a biochemical blood analysis, which runs from $100 to $200, and specialized care such as a consultation with an oncohematologist ranging from $300 to $500. Total expenses depend on the disease stage, specific drug regimens, and hospital tier. Most advanced hematologic care is concentrated in Vienna.
Typical Myeloma Treatment Costs in Austria
Bookimed Expert Insight: Patients seeking personalized protocols should prioritize specialists with research backgrounds in monoclonal gammopathies. Professor Johannes Drach at Confraternitaet Private Hospital leads a dedicated myeloma program, offering deep expertise in chromosomal changes. For highly complex cases, Vienna General Hospital (AKH) provides immense safety through 42 university clinics. These top-tier facilities are ideal for international patients requiring multidisciplinary coordination or clinical trial access.
| Turkey | Austria | Spain | |
| Plasmapheresis | from $1,200 | from $2,000 | from $1,800 |
| Therapeutic Apheresis | from $1,350 | - | - |
| Plasma Exchange | from $3,900 | - | - |
| DFPP Plasmapheresis | from $1,850 | - | - |
Univ. Prof. Dr. Wolfgang Köstler is a leading expert in targeted cancer therapies, with over two decades of experience in medical oncology.
Led the Multiple Myeloma and Malignant Lymphoma program at Vienna's university hospital. Dr. Drach is a professor and director of a private clinic.
The doctor is an esteemed gynecologist and obstetrician with 38 years of experience, specializing in operative gynecology, mammology, and oncological gynecology. Skilled in laparoscopic and endoscopic operations on pelvic organs, the doctor is dedicated to advancing medical knowledge through teaching and publications.
Graduating from Vienna State University in 1986, the doctor served at the University Women's Clinic in Vienna, becoming deputy chief physician of the Department of Gynecology and Maternity Care in 1994. Since 2001, the doctor has been the medical director of a private clinic and oversees the Department of Maternity Care.
First-line myeloma treatment in Austria follows international standards centered on transplant eligibility. Eligible patients receive quadruplet induction therapy followed by autologous stem cell transplantation. Specialized centers like Vienna General Hospital (AKH) provide comprehensive oncohematology care. Protocols prioritize targeted biological therapies over traditional chemotherapy for initial management.
Bookimed Expert Insight: Clinical data from Vienna shows a strong focus on academic expertise for myeloma cases. Specialists like Dr. Johannes Drach at Confraternitaet Private Hospital maintain deep ties to the Medical University of Vienna. This ensures patients in private settings benefit from the same research-driven protocols used at the massive Vienna General Hospital (AKH), which manages over 500,000 patients annually.
Patient Consensus: Patients note that treatment decisions depend more on physical fitness than cancer stage. Many are relieved to find tailored plans that use targeted drugs instead of standard chemotherapy to manage side effects.
Advanced immunotherapies like CAR T-cell therapy and bispecific antibodies are available in Austria at specialized academic centers. Treatment is coordinated through the Austrian CAR-T Cell Network. Facilities like Vienna General Hospital (AKH) provide these EMA-approved therapies for multiple myeloma and other hematological malignancies.
Bookimed Expert Insight: Vienna General Hospital (AKH) is a major hub for myeloma care. It serves nearly 600,000 patients annually and functions as a clinical city. Doctors like Prof. Johannes Drach specialize specifically in multiple myeloma. His international background at centers like M. D. Anderson ensures patients access global-standard protocols locally in Vienna. This concentrated expertise is vital for managing complex immunotherapy side effects.
Patient Consensus: Patients note that while these drugs are approved, the real challenge is timing referrals before the disease progresses too far. Experts emphasize that starting the eligibility journey early is key to securing a spot at university-based transplant centers.
Leading Austrian hospitals for multiple myeloma management include the Vienna General Hospital (AKH) and specialized private centers like Döbling Private Hospital. These institutions offer advanced hematology divisions. They provide autologous stem cell transplants and clinical trials. Many facilities hold ISO and JCI certifications for safety.
Bookimed Expert Insight: While large university hospitals like AKH offer massive research capacity, private clinics in Vienna provide faster access to the same specialized professors. Prof. Dr. Johannes Drach, for example, brings his experience from the university hospital system directly to the private sector. This allows patients to receive high-level expertise without the wait times typical of a 2,200-bed public institution.
Patient Consensus: Patients emphasize choosing national referral centers over regional clinics. They prioritize centers that handle stem cell transplants and offer dedicated myeloma specialist coordination for long-term monitoring.
Austrian Myeloma Registry data shows 10-year survival rates reached 56% for recent patient cohorts. This represents a significant improvement from 21% recorded in 2005. Outcomes are driven by universal drug access and rapid reimbursement for modern combination therapies like proteasome inhibitors.
Bookimed Expert Insight: While registry data provides national trends, Austria's high survival rates are linked to massive infrastructure hubs like Vienna General Hospital (AKH). This facility serves 595,000 patients annually and includes 42 university departments. The data reflects a system where large-scale university hospitals integrate new drug protocols much faster than smaller regional clinics. If you seek treatment in Austria, selecting a high-volume academic center often ensures access to the specific sequential salvage therapies that drive the 20% long-term survival rate in late-stage cases.
Patient Consensus: Patients note that real-world outcomes often depend on how quickly centers adapt after detecting rising tumor markers. They emphasize that while registry statistics are encouraging, managing daily side effects like neuropathy remains a primary concern during maintenance therapy.